Ingrezza Lawsuits Over Safety?

[anonymous]

When do the lawsuits start to get filed against Neurocrine over Ingrezza's safety profile and Long Term Care? This is being brought up more and more. I wonder if the AE and Deaths are the reason for the 20 mg dose?

 

[anonymous]

Too bad the drug didnt work for pediatric tourette's

 

[anonymous]

Too bad the drug didnt work for pediatric tourette's

I think the original poster was talking about Ingrezza being a dirty drug. It is a good question. How many of the deaths are linked to Long Term Care patients?

 

[anonymous]

Sounds like someone who didn't get the job here. We know how mad you must be not joining us but nice try in stirring the pot. Move along loser.

 

[anonymous]

When do the lawsuits start to get filed against Neurocrine over Ingrezza's safety profile and Long Term Care? This is being brought up more and more. I wonder if the AE and Deaths are the reason for the 20 mg dose?

I get the dirty drug comment, but I usually hear that phrase regarding multiple receptors.

What caught my attention is the low dose. It's 25% of the recommended dose. Seems low even for poor metabolism, or renal impairment. Who needs such a low dose?

 

[anonymous]

I get the dirty drug comment, but I usually hear that phrase regarding multiple receptors.

What caught my attention is the low dose. It's 25% of the recommended dose. Seems low even for poor metabolism, or renal impairment. Who needs such a low dose?

Nobody needs this and physicians should stay away. This drug isn't safe in any population simply due to all the drug interactions in this patient sensitive population. You are simply asking for trouble.

 

[anonymous]

I get the dirty drug comment, but I usually hear that phrase regarding multiple receptors.

What caught my attention is the low dose. It's 25% of the recommended dose. Seems low even for poor metabolism, or renal impairment. Who needs such a low dose?

Are they for sure coming out with a lower dose or is that just gossip? Ingrezza's safety concerns is a popular topic. So I would think a lower dose would make sense. Right?

 

[anonymous]

Sounds like someone who didn't get the job here. We know how mad you must be not joining us but nice try in stirring the pot. Move along loser.

Interesting...Why would you deflect on the posters question and attack them? Why not answer the question? He/She brings up a good point. Do you know our product? Have you looked at the FDA AE profile? 9-10x more deaths than Austedo. 10x more Serious AEs then Austedo. 20x more reported AEs then Austedo. We have a serious problem with our drug and I think the comment on lower dosing has a point. Maybe that is how we plan on addressing the AE issue? The weird part is that Austedo also has HD patients. Our product does not have that indication and yet we have serious AE issues. You would think Austedo would have a higher AE problem since they have higher risk patients and more indications. We are the #1 selling brand but not by that much to justify such a big difference in AEs. So, I think this is why we are coming out with various doses and maybe a lower dose at 20.

 

[anonymous]

Interesting...Why would you deflect on the posters question and attack them? Why not answer the question? He/She brings up a good point. Do you know our product? Have you looked at the FDA AE profile? 9-10x more deaths than Austedo. 10x more Serious AEs then Austedo. 20x more reported AEs then Austedo. We have a serious problem with our drug and I think the comment on lower dosing has a point. Maybe that is how we plan on addressing the AE issue? The weird part is that Austedo also has HD patients. Our product does not have that indication and yet we have serious AE issues. You would think Austedo would have a higher AE problem since they have higher risk patients and more indications. We are the #1 selling brand but not by that much to justify such a big difference in AEs. So, I think this is why we are coming out with various doses and maybe a lower dose at 20.

Says the Austedo rep who couldn't get a job with Neurocrine.

 

[anonymous]

I don't think you know your own drug that well. Before you keep saying other people want to be like you...have you checked out the fda Adverse Event profile for ingrezza? The guy is right. Your drug has problems.

I think you keep deflecting the question because you know little about your drug or don't know how to answer for the high number of deaths

 

[anonymous]

I don't think you know your own drug that well. Before you keep saying other people want to be like you...have you checked out the fda Adverse Event profile for ingrezza? The guy is right. Your drug has problems.

I think you keep deflecting the question because you know little about your drug or don't know how to answer for the high number of deaths

You seem to struggle with rejection. Sorry you were not selected for the job. Now run along loser.

 

[anonymous]

Interesting...Why would you deflect on the posters question and attack them? Why not answer the question? He/She brings up a good point. Do you know our product? Have you looked at the FDA AE profile? 9-10x more deaths than Austedo. 10x more Serious AEs then Austedo. 20x more reported AEs then Austedo. We have a serious problem with our drug and I think the comment on lower dosing has a point. Maybe that is how we plan on addressing the AE issue? The weird part is that Austedo also has HD patients. Our product does not have that indication and yet we have serious AE issues. You would think Austedo would have a higher AE problem since they have higher risk patients and more indications. We are the #1 selling brand but not by that much to justify such a big difference in AEs. So, I think this is why we are coming out with various doses and maybe a lower dose at 20.

"Why would you deflect someone's question and attack them?"

When I worked at the cringe that was management 101

 

[anonymous]

You seem to struggle with rejection. Sorry you were not selected for the job. Now run along loser.

Must be worse then we thought.

You are still not answering the question. So the lawsuits must be happening

 

[anonymous]

Surely all this can't be fore real. Why has our senior leadership not addressed this. You are putting us in harms way in the field if this in fact true. How are we to respond with our customers if they are aware of these allegations?

 

[anonymous]

We have an entire new team of neuro reps beginning our journey with company on 1/31. Please say this isn’t so? We’re we mislead? This can’t be true.

 

[anonymous]

We have an entire new team of neuro reps beginning our journey with company on 1/31. Please say this isn’t so? We’re we mislead? This can’t be true.

If in fact all this is true, it won't be the first time in pharma where an expansion is shorter lived than the product messaging. There could be a lot of new folks coming over here who will be gone within weeks. Those of us who are fortunate to already in be place, might be looking at some re-structure as well. There are already way too many of us stepping all over each other and neurology wont touch our product not to mention a 3rd in line "me too" POS drug.

 

[anonymous]

Surely all this can't be fore real. Why has our senior leadership not addressed this. You are putting us in harms way in the field if this in fact true. How are we to respond with our customers if they are aware of these allegations?

This is public information on the FDA website. Whoever originated this post is telling the truth

 

[anonymous]

If in fact all this is true, it won't be the first time in pharma where an expansion is shorter lived than the product messaging. There could be a lot of new folks coming over here who will be gone within weeks. Those of us who are fortunate to already in be place, might be looking at some re-structure as well. There are already way too many of us stepping all over each other and neurology wont touch our product not to mention a 3rd in line "me too" POS drug.

wait so this brand new neuro field force already is on shaky ground before Mondays start date?

 

[anonymous]

wait so this brand new neuro field force already is on shaky ground before Mondays start date?

LOL! It is the old school Pfizer model. Go out and hire all your competitors top reps and offer them very high salaries/benefits to come over. Then have them go out in the field for 6-8 months and call on everything. After that 6-8 months, have lay offs. So the high salaries do not need to be paid, vested income is kept, no need to worry about company cars at Neurocrine, and the laid off sales reps that were brought over from your competitor are no longer working for your competitor. It looks like Neurocrine is going old school and cut throat with their sales force. I wonder if the managers in the hiring process told the new hires "we are going to work you hard here". Well, at least for the next six months, then they will lay us off.

 

[anonymous]

Well you know the old saying, something about the grass?